Cizzle Bio Study Supports CIZ1B for Early Lung Cancer
Dallas, Texas, September 1, 2026 Cizzle Bio, Inc. has announced the publication of a new peer-reviewed study providing additional...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Dallas, Texas, September 1, 2026 Cizzle Bio, Inc. has announced the publication of a new peer-reviewed study providing additional...
SAN ANTONIO, September 1, 2026 bioAffinity Technologies, Inc. is advancing the potential use of its noninvasive CyPath® Lung test...
SAN ANTONIO, July 27, 2026 bioAffinity Technologies, Inc. announced the publication of a comprehensive clinical review and white paper...
SAN ANTONIO, TX, March 17, 2026 bioAffinity Technologies, Inc. has released a new clinical case study demonstrating how its...
